Towards precision medicine for sepsis patients.
作者信息
Pickkers Peter, Kox Matthijs
机构信息
Department of Intensive Care Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Internal mail 710, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands.
Radboud Center for Infectious Diseases (RCI), Nijmegen, The Netherlands.
出版信息
Crit Care. 2017 Jan 12;21(1):11. doi: 10.1186/s13054-016-1583-z.
Abstract
摘要
相似文献
1
Towards precision medicine for sepsis patients.迈向脓毒症患者的精准医学
Crit Care. 2017 Jan 12;21(1):11. doi: 10.1186/s13054-016-1583-z.
2
Precision Immunotherapy for Sepsis.精准免疫疗法治疗败血症。
Front Immunol. 2018 Sep 5;9:1926. doi: 10.3389/fimmu.2018.01926. eCollection 2018.
3
Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study.脓毒症3 - 4天后单核细胞程序性死亡配体-1表达与脓毒症患者的风险分层及死亡率相关：一项前瞻性队列研究
Crit Care. 2016 May 9;20(1):124. doi: 10.1186/s13054-016-1301-x.
4
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis.程序性细胞死亡蛋白1/程序性死亡配体1通路：脓毒症的新靶点。
Chin Med J (Engl). 2017 Apr 20;130(8):986-992. doi: 10.4103/0366-6999.204113.
5
Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?脓毒症的免疫治疗：死胡同还是需要个性化评估？
Arch Immunol Ther Exp (Warsz). 2017 Feb;65(1):37-49. doi: 10.1007/s00005-016-0415-9. Epub 2016 Aug 24.
6
Should blood transfusion be individualised? We are not sure.输血应该个体化吗？我们不确定。
Intensive Care Med. 2015 Nov;41(11):1980-2. doi: 10.1007/s00134-015-4034-4. Epub 2015 Sep 10.
7
Monitoring immunomodulation in patients with sepsis.监测脓毒症患者的免疫调节。
Expert Rev Mol Diagn. 2021 Jan;21(1):17-29. doi: 10.1080/14737159.2020.1851199. Epub 2020 Dec 10.
8
Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.非小细胞肺癌中PD-1/PD-L1检查点抑制剂的伴随诊断检测
Expert Rev Mol Diagn. 2016;16(2):131-3. doi: 10.1586/14737159.2016.1117389. Epub 2015 Nov 27.
9
A path to precision in the ICU.重症监护病房的精准之路。
Crit Care. 2017 Apr 3;21(1):79. doi: 10.1186/s13054-017-1653-x.
10
Ready or not: personalized medicine is coming. IEEE Pulse talks with Michael Snyder about its potential.准备好了吗：个性化医疗即将到来。《IEEE 脉动》杂志与迈克尔·斯奈德探讨了其潜力。
IEEE Pulse. 2014 May-Jun;5(3):45-7. doi: 10.1109/MPUL.2014.2309580.
引用本文的文献
1
Immune cell phenotypes as causal factors in liver disease progression revealed by Mendelian randomization.孟德尔随机化揭示免疫细胞表型作为肝脏疾病进展的因果因素
Sci Rep. 2025 Apr 12;15(1):12685. doi: 10.1038/s41598-025-97429-x.
2
Sepsis subphenotypes: bridging the gaps in sepsis treatment strategies.脓毒症亚表型：弥合脓毒症治疗策略的差距
Front Immunol. 2025 Feb 6;16:1546474. doi: 10.3389/fimmu.2025.1546474. eCollection 2025.
3
MiRNAs and Neutrophil-Related Membrane Proteins from Plasma-Derived Extracellular Vesicles for Early Prediction of Organ Dysfunction and Prognosis in Septic Patients.血浆来源细胞外囊泡中的微小RNA与中性粒细胞相关膜蛋白用于脓毒症患者器官功能障碍及预后的早期预测
J Inflamm Res. 2024 Dec 4;17:10347-10369. doi: 10.2147/JIR.S492902. eCollection 2024.
4
Causal relationship between the immune phenotype of monocytes and myasthenia gravis: A Mendelian randomization study.单核细胞免疫表型与重症肌无力之间的因果关系：一项孟德尔随机化研究。
Heliyon. 2024 Feb 20;10(5):e26741. doi: 10.1016/j.heliyon.2024.e26741. eCollection 2024 Mar 15.
5
Editorial: Sepsis: studying the immune system to highlight biomarkers for diagnosis, prognosis and personalized treatments.社论：脓毒症：研究免疫系统以突出用于诊断、预后和个性化治疗的生物标志物
Front Immunol. 2023 Nov 22;14:1325020. doi: 10.3389/fimmu.2023.1325020. eCollection 2023.
6
Priorities for paediatric critical care research: a modified Delphi study by the Australian and New Zealand Intensive Care Society Paediatric Study Group.儿科重症监护研究的优先事项：澳大利亚和新西兰重症监护学会儿科研究小组的一项改良德尔菲研究。
Crit Care Resusc. 2023 Oct 18;23(2):194-201. doi: 10.51893/2021.2.oa6. eCollection 2021 Jun.
7
Fucoxanthin Alleviates Lipopolysaccharide-Induced Inflammation and Immunosuppression in RAW264.7 Macrophages.岩藻黄质可减轻脂多糖诱导的 RAW264.7 巨噬细胞炎症和免疫抑制。
Dokl Biochem Biophys. 2023 Apr;509(1):81-85. doi: 10.1134/S1607672922600166. Epub 2023 Jun 20.
8
Time to treatment and mortality for clinical sepsis subtypes.临床脓毒症亚型的治疗时间和死亡率。
Crit Care. 2023 Jun 15;27(1):236. doi: 10.1186/s13054-023-04507-5.
9
Premorbid use of selective beta-blockers improves sepsis incidence and course: Human cohort and animal model studies.病前使用选择性β受体阻滞剂可改善脓毒症的发生率和病程：人类队列研究和动物模型研究
Front Med (Lausanne). 2023 Apr 18;10:1105894. doi: 10.3389/fmed.2023.1105894. eCollection 2023.
10
Sepsis heterogeneity.脓毒症异质性。
World J Pediatr. 2023 Oct;19(10):919-927. doi: 10.1007/s12519-023-00689-8. Epub 2023 Feb 3.
本文引用的文献
1
Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study.单核细胞人类白细胞抗原-DR表达及刺激后肿瘤坏死因子α产生作为严重脓毒症预后预测指标的比较：一项前瞻性观察性研究
Crit Care. 2016 Oct 20;20(1):334. doi: 10.1186/s13054-016-1505-0.
2
Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.前沿科学：脓毒症患者的免疫功能缺陷与PD-1或PD-L1表达相关，且可通过靶向PD-1或PD-L1的抗体得以恢复。
J Leukoc Biol. 2016 Dec;100(6):1239-1254. doi: 10.1189/jlb.4HI0616-255R. Epub 2016 Sep 26.
3
Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study.脓毒症3 - 4天后单核细胞程序性死亡配体-1表达与脓毒症患者的风险分层及死亡率相关：一项前瞻性队列研究
Crit Care. 2016 May 9;20(1):124. doi: 10.1186/s13054-016-1301-x.
4
Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis.严重脓毒症患者白细胞能量代谢存在广泛缺陷，导致免疫麻痹。
Nat Immunol. 2016 Apr;17(4):406-13. doi: 10.1038/ni.3398. Epub 2016 Mar 7.
5
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).《脓毒症及脓毒性休克第三次国际共识定义（脓毒症-3）》
JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
6
Sepsis-induced immune dysfunction: can immune therapies reduce mortality?脓毒症诱导的免疫功能障碍：免疫疗法能否降低死亡率？
J Clin Invest. 2016 Jan;126(1):23-31. doi: 10.1172/JCI82224. Epub 2016 Jan 4.
7
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.白细胞介素-1受体阻断与具有巨噬细胞活化综合征特征的脓毒症患者死亡率降低相关：对一项既往III期试验的重新分析
Crit Care Med. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402.
8
Immune checkpoint blockade: a common denominator approach to cancer therapy.免疫检查点阻断：癌症治疗的一种通用方法。
Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6.
9
Reactivation of multiple viruses in patients with sepsis.脓毒症患者中多种病毒的再激活。
PLoS One. 2014 Jun 11;9(2):e98819. doi: 10.1371/journal.pone.0098819. eCollection 2014.
10
Why have clinical trials in sepsis failed?为什么脓毒症临床试验会失败？
Trends Mol Med. 2014 Apr;20(4):195-203. doi: 10.1016/j.molmed.2014.01.007. Epub 2014 Feb 24.
Zotero 插件